On Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) opened higher 5.23% from the last session, before settling in for the closing price of $26.75. Price fluctuations for AKRO have ranged from $11.25 to $50.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -24.85% at the time writing. With a float of $58.10 million, this company’s outstanding shares have now reached $69.43 million.
In an organization with 56 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.83%, operating margin of -82458.8%, and the pretax margin is -71892.96%.
Akero Therapeutics Inc (AKRO) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Akero Therapeutics Inc is 16.32%, while institutional ownership is 98.58%. The most recent insider transaction that took place on Oct 01 ’24, was worth 281,770. In this transaction Chief Operating Officer of this company sold 10,000 shares at a rate of $28.18, taking the stock ownership to the 226,286 shares. Before that another transaction happened on Oct 01 ’24, when Company’s Officer proposed sale 110,716 for $28.51, making the entire transaction worth $3,156,513.
Akero Therapeutics Inc (AKRO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -24.85% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Check out the current performance indicators for Akero Therapeutics Inc (AKRO). In the past quarter, the stock posted a quick ratio of 24.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.41, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -3.81 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.48 million. That was inferior than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.04%. Additionally, its Average True Range was 1.44.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 85.68%, which indicates a significant increase from 49.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.29% in the past 14 days, which was lower than the 51.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.55, while its 200-day Moving Average is $23.95. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $29.17. Second resistance stands at $30.19. The third major resistance level sits at $31.36. If the price goes on to break the first support level at $26.97, it is likely to go to the next support level at $25.80. Assuming the price breaks the second support level, the third support level stands at $24.78.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
There are currently 69,151K shares outstanding in the company with a market cap of 1.95 billion. Presently, the company’s annual sales total 0 K according to its annual income of -151,760 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -55,990 K.
